Tom K. Birkenhager

Tom K. Birkenhager

Auto-generated profile, based on publicly available information

Tom K. Birkenhager

Department of Psychiatry, Erasmus UMC, Rotterdam, the Netherlands; Collaborative Antwerp Psychiatric Research Institute (CAPRI), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2012 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
BDBram Dierckx
Bram Dierckx
WHWillemijn T Heijnen
Willemijn T Heijnen
WBWalter W van Den Broek
Walter W van Den Broek
TBTom K Birkenhäger
Tom K Birkenhäger

1 March 2012 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
TBTom K. Birkenhäger
Tom K. Birkenhäger
SGSarah Geldermans
Sarah Geldermans
WBWalter W. Van Den Broek
Walter W. Van Den Broek
NBNico van Beveren
Nico van Beveren
DFDurk Fekkes
Durk Fekkes

1 December 2005 in The Journal of ECT
Verified
Journal Article
Closed access
TBTom K Birkenhäger
Tom K Birkenhäger
WBWalter W van Den Broek
Walter W van Den Broek
PMPaul G H Mulder
Paul G H Mulder
ALAriejan de Lely
Ariejan de Lely
Background: Psychotic depression is thought to have a higher relapse frequency after electroconvulsive therapy (ECT) compared with nonpsychotic depression, although this observation is contradicted by previous studies that have found the opposite. In this study, the 1-year risk of relapse after successful ECT was determined prospectively in patients with psychotic depression and compared with the risk of relapse observed for depressed patients without psychotic features. Method: Fifty-nine responders to ECT (a decrease in Hamilton Rating Scale for Depression [HAM-D] score ≥ 50%) were followed for 1 year: 29 with and 30 without psychotic features. Relapse was defined as meeting DSM-IV criteria for major depressive disorder and a HAM-D score ≥16. The frequency of relapse after 4 and 12 months was compared between both samples, adjusted for the co-variables duration of the index episode and type of post-ECT pharmacotherapy. Results: At both 4 and 12 months after ECT, instances of relapse were significantly lower in patients with psychotic depression compared with nonpsychotic patients: 3/28 (11%) versus 16/27 (59%) and 4/27 (15%) versus 19/28 (68%), respectively. Conclusions: The main finding of the present study is the favorable 1-year outcome for patients with psychotic depression after response to ECT with a trend toward the same result at 4 months. The 1-year outcome of the total sample is also more favorable than expected.

15 November 2004 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
TBTom K. Birkenhäger
Tom K. Birkenhäger
WBWalter W. van Den Broek
Walter W. van Den Broek
PMPaul G. Mulder
Paul G. Mulder
JBJan A. Bruijn
Jan A. Bruijn
PMPeter Moleman
Peter Moleman
TextabstractBackground: The aim of this study was to examine whether phenelzine is a suitable alternative to tranylcypromine in antidepressant-resistant depression. Method: A total of 77 severely depressed inpatients, meeting the DSM-IV criteria for major depressive disorder, who failed to respond to fixed plasma level treatment with either tricyclic antidepressants or fluvoxamine were withdrawn from psychotropic medication and included in a double-blind flexible-dose 5-week comparison of tranylcypromine and phenelzine. Results: Of the 77 patients, 67 (87%) completed the trial, of whom 35 (52%) responded. No significant differences in response between both drugs were observed. Seventeen (44%) of 39 patients responded to tranylcypromine and 18 (47%) of 38 to phenelzine (≥ 50% reduction in Hamilton Rating Scale for Depression [HAM-D] score). The mean reduction in HAM-D score was 10.4 ± 8.3 for the tranylcypromine sample versus 8.3 ± 8.4 for the phenelzine-treated patients. Only a few patients (10%) used concomitant psychotropic medication. A substantial number of patients experienced severe side effects, mainly dizziness, agitation, and insomnia; the incidence was the same in both samples (21%). Conclusion: No difference in efficacy was observed between both monoamine oxidase inhibitors in a sample of patients with severe antidepressant-refractory depression. Phenelzine appears to be a suitable alternative to tranylcypromine

8 September 2020 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
KHKaat Hebbrecht
Kaat Hebbrecht
EGErik J. Giltay
Erik J. Giltay
TBT.K. Birkenhäger
T.K. Birkenhäger
BSBernard Sabbe
Bernard Sabbe
EVEsmée Verwijk
Esmée Verwijk
LDLinda Van Diermen
Linda Van Diermen

1 October 2010 in Journal of Affective Disorders
Verified
Journal Article
Closed access
TBTom K. Birkenhäger
Tom K. Birkenhäger
EPEsther M. Pluijms
Esther M. Pluijms
MJMichel R. Ju
Michel R. Ju
PMPaul G. Mulder
Paul G. Mulder
WBWalter W. van Den Broek
Walter W. van Den Broek